NSCLC patients harboring epidermal growth factor receptor (EGFR) mutations may benefit from tyrosine kinase inhibitors (TKIs); however, EMT can promote TKI resistance through interference with apoptosis[53]. Here, EGFR is linked to non-small cell lung carcinoma.